Jubilant Pharmova Q1 FY27 Results: Revenue Rs 2,229 Cr, PAT Rs 56 Cr and Key Highlights

Jubilant Pharmova Q1 FY27 results were declared on August 10, 2026 on a consolidated basis. Revenue expanded +17.29% YoY to Rs 2,229 Cr from Rs 1,900 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.

Operating profit stood at Rs 120 Cr (-36.97% YoY). PAT came in at Rs 56 Cr (-45.03% YoY), reflecting the key financial metrics of Jubilant Pharmova Q1 FY27 results.

Click Here – Get Free Investment Predictions

Jubilant Pharmova Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Cr)	Q1 FY26 (Rs Cr)	YoY Change
Jubilant Pharmova Revenue	2,229	1,900	+17.29%
Operating Profit	120	191	-36.97%
Net Profit (PAT)	56	102	-45.03%
Reporting Basis	Consolidated

Jubilant Pharmova Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Jubilant Pharmova Q1 FY27 results reflect under-pressure fundamentals. Revenue momentum were evident with the top line reaching Rs 2,229 Cr for the April to June 2026 quarter.

Operating profit contracted -36.97% YoY. PAT of Rs 56 Cr reflects -45.03% YoY movement. Investors tracking Jubilant Pharmova Q1 FY27 results will note these as key FY27 milestones.

Key Business Factors in Jubilant Pharmova Q1 FY27 Results

Revenue Expansion in Q1 FY27

Jubilant Pharmova Q1 FY27 results show revenue expanding +17.29% YoY to Rs 2,229 Cr from Rs 1,900 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.

Margin Pressure from Cost Headwinds

Operating profit in Jubilant Pharmova Q1 FY27 results stood at Rs 120 Cr (-36.97% YoY). Input cost inflation and competitive dynamics weighed on operating profitability.

PAT Trajectory and Profitability

PAT in Jubilant Pharmova Q1 FY27 results was Rs 56 Cr (-45.03% YoY), reflecting near-term operational challenges.

Dividend Details

No dividend was declared alongside Jubilant Pharmova Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.

FY27 Outlook for Jubilant Pharmova

Following Jubilant Pharmova Q1 FY27 results, management has focused on a recovery-driven strategy centred on cost reduction, revenue diversification, and return to profitability in the pharmaceuticals segment. Investors tracking Jubilant Pharmova Q1 FY27 results should consult a SEBI-registered financial advisor.

Jubilant Pharmova Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Jubilant Pharmova live price and get daily stock recommendations.

Jubilant Pharmova shares were trading higher at Rs 962.7 (+3.29%) on August 10, 2026, reflecting investor sentiment on Jubilant Pharmova Q1 FY27 results and the near-term sector outlook. The CMP of Rs 962.7 on the results date reflects broader sentiment toward the pharmaceuticals space.

Key Risks for Jubilant Pharmova

Sector-Specific Risks

USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.

Valuation and Earnings Risk

Sustained margin compression and limited near-term earnings visibility may delay re-rating.

Operational and Financial Risk

Subsidiary-level underperformance could drag consolidated PAT lower in subsequent quarters.

Conclusion

Jubilant Pharmova Q1 FY27 results reflect under-pressure performance with revenue at Rs 2,229 Cr and PAT at Rs 56 Cr on a Consolidated basis. Sector tailwinds and operational discipline will shape the FY27 trajectory. Investors should review management commentary before taking any position.

Frequently Asked Questions on Jubilant Pharmova Q1 FY27 Results

When were Jubilant Pharmova Q1 FY27 results declared?

Ans. Jubilant Pharmova Q1 FY27 results were declared on August 10, 2026, covering the April–June 2026 quarter on a Consolidated basis.

What was Jubilant Pharmova revenue in Q1 FY27?

Ans. Revenue in Jubilant Pharmova Q1 FY27 results was Rs 2,229 Cr, +17.29% YoY from Rs 1,900 Cr in Q1 FY26.

What was Jubilant Pharmova PAT in Q1 FY27?

Ans. Net profit in Jubilant Pharmova Q1 FY27 results was Rs 56 Cr (-45.03% YoY).

Did Jubilant Pharmova declare a dividend in Q1 FY27?

Ans. No dividend was announced alongside Jubilant Pharmova Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.

What is the FY27 outlook for Jubilant Pharmova?

Ans. Management has guided operational restructuring and return to profitability for FY27. Sector demand and execution will be key monitorables.

How did Jubilant Pharmova stock react to Q1 FY27 results?

Ans. Jubilant Pharmova shares were higher at Rs 962.7 (+3.29%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.